MAP2K7 and neoplasm: These small molecule inhibitors often have anti-tumor activity by inhibiting EGFR, Raf/MEK/ERK and other signaling pathways in addition to inhibiting the VEGF pathway.[25] Bevacizumab, ramucirumab, aflibercept, and regorafenib are the primary anti-VEGF medications presently utilized in persons with mCRC.[26]